Trials / Conditions / Persistent Infection

Persistent Infection

13 registered clinical trials studyying Persistent Infection — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Evaluation of Different Medicaments in the Management of Necrotic Primary Molars by Lesion Sterilization and T NCT06926322	Ain Shams University	N/A
Completed	A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis NCT06159725	Clarametyx Biosciences, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolesc NCT06243666	Xiamen University	—
Recruiting	New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis NCT05621343	Region Skane	—
Unknown	The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Femal NCT05045755	Jun Zhang	—
Unknown	The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female NCT04969445	Jun Zhang	—
Unknown	Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls ( NCT04704908	Jun Zhang	—
Completed	Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female NCT05426148	Xiamen Innovax Biotech Co., Ltd	Phase 4
Unknown	The Effectiveness of Hyperpure Chlorine Dioxide and Sodium Hypochlorite Irrigants in Endodontic Retreament in NCT04954638	Eniko Vaszine Szabo	—
Completed	Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls NCT03206255	Jun Zhang	—
Completed	Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females NCT02740777	Shanghai Zerun Biotechnology Co.,Ltd	Phase 2
Completed	A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls NCT02562508	Jun Zhang	Phase 3
Completed	Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine NCT01735006	Xiamen University	Phase 3